Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Degree

Medical Specialty

Submit

Strategies for Optimal HIV Treatment and Prevention: Considering Bictegravir in Pregnancy

Source: Strategies for Optimal HIV Treatment and Prevention

Should you continue or switch ART for someone who becomes pregnant while virologically suppressed on a bictegravir-containing regimen? In this case example, learn about available data and recommendations for the use of bictegravir in pregnancy, as well as key considerations for deciding whether to switch ART for someone who becomes pregnant while virologically suppressed on a bictegravir-containing regimen.

William R. Short, MD, MPH, AAHIVS

Released: September 28, 2022

Information on this Educational Activity

Faculty

William R. Short, MD, MPH, AAHIVS

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS: non-CME/CE services: Janssen; consultant: ViiV Healthcare.

Staff

Jessica Adams, PharmD, BCPS, AAHIVP

Scientific Director

Jessica Adams, PharmD, BCPS, has no relevant financial relationships to disclose.

Ramya Moorthy

Clinical Editor

Ramya Moorthy has no relevant financial relationships to disclose.

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant financial relationships to disclose.

Ian Murphy, PhD

Ian Murphy, PhD, had no relevant financial relationships to disclose.

Program Medium